» Articles » PMID: 25728929

Systematic Review with Meta-analysis: Pharmacological Interventions for Eosinophilic Oesophagitis

Overview
Date 2015 Mar 3
PMID 25728929
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Eosinophilic oesophagitis (EoE) is a growing cause of dysphagia. Current therapies include dietary manipulation, steroids and biological drugs.

Aim: To perform a systematic review and summarise the effect of different medical interventions on EoE.

Methods: Two reviewers searched Pubmed and Embase for studies on treatment for EoE. We included randomised controlled trials (RCT) limited to pharmacological interventions. Two reviewers selected studies. Meta-analysis was done using random effects model to estimate odds ratio (OR). Heterogeneity was determined by Cochran's Q statistic and I(2) .

Results: Seventeen references met our inclusion criteria. Eleven RCTs involving 455 participants were included in the meta-analysis. 325 participants were evaluated for symptomatic improvement and 330 were evaluated for histological remission. Symptomatic improvement with topical steroids (7 studies, 250 participants) compared to the control group (placebo or PPI) was noted (OR: 3.03, 95% confidence interval, CI: 1.57-5.87). Histological remission was also noted in nine studies involving 330 participants (OR: 13.66, 95% CI: 2.65-70.34) comparing topical steroids to a control (placebo or PPI). There was no difference between anti-IL-5 drugs and placebo in terms of symptomatic improvement (OR: 0.69, 95% CI: 0.34-1.42).

Conclusions: Topical steroids induce significant symptomatic and histological remission, and should be considered as a first line treatment. Anti-IL-5 therapy has a minor effect on eosinophilic oesophagitis. Future research in eosinophilic oesophagitis should standardise methodology according to published guidelines to improve quality and allow direct comparison between therapies.

Citing Articles

Pharmacologic Treatment of Eosinophilic Esophagitis: Efficacious, Likely Efficacious, and Failed Drugs.

Schoepfer A, Safroneeva E Inflamm Intest Dis. 2024; 9(1):199-209.

PMID: 39474328 PMC: 11521425. DOI: 10.1159/000540275.


Eosinophilic Esophagitis beyond Eosinophils - an Emerging Phenomenon Overlapping with Eosinophilic Esophagitis: Collegium Internationale Allergologicum (CIA) Update 2023.

Salvador Nunes V, Straumann A, Salvador Nunes L, Schoepfer A, Greuter T Int Arch Allergy Immunol. 2023; 184(5):411-420.

PMID: 36972571 PMC: 10337666. DOI: 10.1159/000529910.


Does eosinophilic esophagitis exist in India?.

Nagarajan K, Krishnamurthy A, Yelsangikar A, Mallappa R, Bhat V, Narasimhamurthy V Indian J Gastroenterol. 2023; 42(2):286-291.

PMID: 36930398 DOI: 10.1007/s12664-022-01313-9.


Histological remission of eosinophilic esophagitis under asthma therapy with IL-5 receptor monoclonal antibody: A case report.

Huguenot M, Bruhm A, Essig M World J Clin Cases. 2022; 10(14):4502-4508.

PMID: 35663093 PMC: 9125258. DOI: 10.12998/wjcc.v10.i14.4502.


British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults.

Dhar A, Haboubi H, Attwood S, Auth M, Dunn J, Sweis R Gut. 2022; 71(8):1459-1487.

PMID: 35606089 PMC: 9279848. DOI: 10.1136/gutjnl-2022-327326.